Needham Reiterates Buy on G1 Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on G1 Therapeutics (NASDAQ:GTHX) and maintained a $12 price target.
May 22, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on G1 Therapeutics and maintained a $12 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $12 price target by a reputable analyst can boost investor confidence in G1 Therapeutics, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100